article thumbnail

Purolite and Repligen to commercially launch novel CH1 affinity resin

BioPharma Reporter

Ion exchange resin manufacturer Purolite and bioprocessing technology firm Repligen have announced the commercial launch of Praesto CH1, an affinity resin designed to purify specialized mAbs such as bispecifics and recombinant antibody fragments.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Nick Pittman, Marketing Manager, Global Biopharmaceutical Business, Waters Corporation, on: ‘Robust multi-level LC-MS workflows for biosimilar comparability assessment’. Kris Ver Donck, Vice President, Marketing & Applications, FOx BIOSYSTEMS, on: ‘Using FO-SPR to select for efficient antigen binders in phage display’.